Key Points

• BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer.

• The setback raises questions about the mRNA vaccine's prospects in treating pancreatic cancer.

• However, it's too early to write off BioNTech's chances.

BioNTech's (NASDAQ: BNTX) shares were flying high in the aftermath of Moderna's (NASDAQ: MRNA) and Merck's (NYSE: MRK) announcement of impressive late-stage results for personalized messenger RNA (mRNA) cancer vaccine intismeran autogene in combination with Keytruda. The surge made sense, considering that BioNTech is developing its own mRNA cancer vaccines.

However, BioNTech's momentum came to a screeching halt with the company's update on Aug. 28, 2026, from a Phase 2 study of mRNA vaccine autogene cevumeran in treating colorectal cancer. BioNTech and its partner, Roche's (OTC: RHHBY) Genentech unit, decided to cancel the clinical trial due to a lack of efficacy. Should this move to throw in the towel worry investors?

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

What is the real impact of BioNTech's setback?

BioNTech's pipeline setback shouldn't have completely surprised investors. The independent Data Safety Monitoring Board (DSMB) for the Phase 2 study of autogene cevumeran concluded in October 2025 that the data were not yet mature enough to support reliable conclusions about efficacy. BioNTech and Genentech decided then to go ahead with the clinical trial.

What is the real impact of the termination of the Phase 2 study of the mRNA vaccine in treating colorectal cancer? It's certainly not as bad as the situation would have been if autogene cevumeran had safety issues. Serious safety concerns would have forced BioNTech to completely abandon the experimental vaccine.

But that isn't the case. BioNTech and Genentech continue to evaluate autogene cevumeran in another Phase 2 study targeting pancreatic cancer.

Both colorectal and pancreatic cancer are "cold" tumors that don't trigger strong immune responses. Moderna's mRNA vaccine achieved successful results in melanoma, a "hot" tumor for which the body's immune system mounts a significant natural response. BioNTech's failure in colorectal cancer, therefore, raises questions about whether or not the vaccine will work in treating pancreatic cancer.

A cause for concern -- but not panic

It's too early to write off BioNTech's prospects in pancreatic cancer, though. Any speculation that the company might reduce emphasis on its mRNA cancer vaccine focus is also premature. BioNTech co-founder and Chief Medical Officer Özlem Türeci stated, "We remain committed to mRNA as a key pillar in our oncology strategy, and our novel combination approaches."

BioNTech continues to advance other experimental mRNA cancer vaccines targeting head and neck cancer and non-small cell lung cancer. Its pipeline also features multiple other types of cancer therapies. The company recently announced that one of them, gotistibart, nearly doubled the median overall survival compared with chemotherapy in previously treated patients with squamous non-small cell lung cancer.

The bottom line is that BioNTech's termination of its Phase 2 study of autogene cevumeran in colorectal cancer is a legitimate cause of concern for investors. However, it isn't a reason to panic about the biotech stock.

Should you buy stock in BioNTech Se right now?

Before you buy stock in BioNTech Se, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BioNTech Se wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $412,074!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,314,319!*

Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of September 18, 2026.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Merck, and Moderna. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy.